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Abstract
Background—Methicillin-resistant Staphylococus aureus (MRSA) is an important nosocomial
and community-associated (CA) pathogen. Recently, a variant of the MRSA USA300 clone emerged
and disseminated in South-America causing important clinical problems.
Methods—S. aureus isolates were prospectively collected (2006 to 2008) from 32 tertiary hospitals
in Colombia, Ecuador, Peru, and Venezuela. MRSA isolates were subjected to antimicrobial
susceptibility testing, pulsed field gel electrophoresis (PFGE), and categorized as healthcare-
associated (HA)-like or CA-like clones based on genotypic characteristics and detection of genes
encoding the Panton-Valentine leukocidin (PVL) and staphylococcal cassette mec (SCCmec) IV.
Additionally, MLST of representative isolates of each major CA-MRSA pulsotype, and detection of
USA300-associated toxins and the arcA gene were performed in all isolates categorized as CA-
MRSA.
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Results—A total of 1570 S. aureus were included; 651 were MRSA (41%), with the highest rates
of MRSA isolation in Peru (62%), and lowest in Venezuela (26%) and 71%, 27%, and 2% were
classified as HA-like, CA-like, and non-CA/HA-like clones, respectively. Only 9 MRSA isolates
were confirmed to have reduced susceptibility to glycopeptides (GISA phenotype). The most
common pulsotype (designated ComA) amongst the CA-like MRSA strains was found in 96% of
isolates with the majority (81%) having ≤6 bands difference with the USA300-0114 strain.
Representative isolates of this clone were ST8 but, unlike the USA300-0114 strain, they harbored a
different SCCmec IV subtype and lacked arcA (an indicator of the arginine catabolic mobile element
(ACME)).
Conclusion—A variant CA-MRSA USA300 clone has now become established in South America
and, in some countries, is endemic in hospital settings.
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Methicillin-resistant Staphylococcus aureus (MRSA) has been recognized as a major cause of
infections worldwide. Although initially recognized as an important nosocomial pathogen,
MRSA is now endemic in the community outside hospitals [1]. Community-associated
methicillin-resistant Staphylococcus aureus (CA-MRSA) infections are caused by highly
virulent strains of S. aureus which can affect healthy individuals [2] and, most worrisome, CA-
MRSA strains have now been increasingly reported as an important cause of nosocomial
infections indicating that they may become endemic in hospital settings [3]. Another important
issue related to the treatment of MRSA infections is the emergence of resistance to vancomycin
[4] and the observation that the effectiveness of vancomycin for the treatment of severe
infections may be compromised [5].
Diverse molecular typing tools have established that the worldwide dissemination of MRSA
is mainly due to a few successful clones [6] with a rather specific geographical pattern [7].
HA-MRSA clones detected in South America have typically belonged to two major genotypes:
i) the Brazilian ST239, SCCmec III (MRSA-ST239-III) [8–9], and ii) the Chilean clone
(MRSA-ST5-I) [8–12]; the later appears to have replaced the Brazilian clone on the continent.
Regarding CA-MRSA, two major clones also have been identified in South America: i) MRSA-
ST30-IV, mainly present in the Southern part of the continent [13,14] and ii) MRSA-ST8-IV
(and its single locus variant (SLV), MRSA-ST923-IV) which is genetically related to MRSA
USA300 and was reported for the first time as the predominant and exclusive genetic lineage
in Colombia [15]. In this work, we report the first prospective, multicentre study of the
molecular epidemiology of MRSA recovered from four Latin American countries in 2006 to
2008.
METHODS
Study Design
The participating centers included 32 high-level care hospitals which were distributed as
follows: i) 22 hospitals in Colombia (located in six cities); ii) 5 hospitals in Ecuador (one city),
iii) 3 hospitals in Peru (one city), and 2 hospitals in Venezuela (one city). The S. aureus isolates
included in this study were collected prospectively from individual patients (repeated isolates
from the same patient were excluded). Each hospital collected 50 to 150 consecutive isolates
which were recovered from January 2006 to January 2008 according to a specific protocol and
monitored by the local coordinator in each country. Clinical specimens included blood,
cerebrospinal fluid (CSF), urine, secretions from complicated skin structures and soft tissue
infections (SSTIs), and post-surgical wound infections (after clinical evaluation), pleural fluid,
Reyes et al. Page 2
Clin Infect Dis. Author manuscript; available in PMC 2010 December 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
bronchoalveolar lavage, pericardial collection, intra-abdominal, or intra-cerebral abscess, bone
tissue from suspected osteomyelitis, arthritis aspirates (in the setting of septic arthritis), and
peritoneal fluid (in the setting of peritonitis including those associated with peritoneal dialysis).
Isolates recovered from catheters, sputum, and those labeled as “skin” without a clinical
justification were excluded. The organisms were identified in the local hospital and, once
included in the protocol, were sent to the reference laboratory (Bogota, Colombia) in a transport
medium (AMIES with charcoal, BBL, Franklin Lakes, NJ USA). Upon arrival, the isolates
were re-identified (see below), and preserved in soy trypticase broth (TSB) with 10% glycerol
at −70°C.
Bacterial isolates and antimicrobial susceptibility testing
Confirmation of the identification at the species level of all S. aureus isolates was performed
by a multiplex PCR assay [16]. The antimicrobial susceptibility profiles of all isolates were
determined by the agar dilution method following the Clinical Laboratory Standards Institute
(CLSI) guidelines [17]. Screening for reduced susceptibility to vancomycin was performed on
all MRSA isolates according to the CLSI guidelines [17]. In addition, all MRSA isolates with
a vancomycin MIC of 1 μg/mL or 2 μg/mL were further screened with two additional agar
methods (Mueller-Hinton supplemented with 5 μg/mL of teicoplanin and brain heart infusion
(BHI) supplemented with 4 μg/mL of vancomycin) as described previously [18,19]. MRSA
isolates which were positive for at least one of the screening tests were additionally tested by
the Etest macromethod (EM) [20]; subsequently, isolates identified as positive by the Etest
were further evaluated by the new Etest GRD VA (32-0.5 μg/mL); TP (32-0.5 μg/mL) strip
(AB BioMeriux S.A., Marcy l’Etoile, France) [21]. The following reference organisms were
used as controls for susceptibility testing, and evaluation of low level glycopeptide resistance
(GISA) and heterogeneous glycopeptide resistance (hGISA): S. aureus ATCC 29213, ATCC
700698 (Mu3; hGISA) and ATCC 700699 (Mu50; GISA).
Molecular typing and detection of genes associated with virulence
The SCCmec types (I to IV) and subtypes were evaluated in all MRSA isolates by multiplex
PCR according to previously reported assays [22–24]. The MRSA strains USA300-0114
(SCCmec type IVa), USA300 (SCCmec type IVb), MR108 (SCCmec type IVc) [25],
JCSC4469 (SCCmec type IVd) [23] and HAR22 (SCCmec IVh) [24] were used as controls for
PCR assays. Pulsed field gel electrophoresis (PFGE) was performed on all MRSA isolates,
with some modifications of a previously described method [26]. Banding patterns were
interpreted according to standard criteria [27]; S. aureus NCTC8325 was used as a molecular
size control and representatives of MRSA strains belonging to the Chilean, Brazilian and
Pediatric clones [12], MRSA NRS 382 (New York/Japan clone), NRS 123 (MRSA USA400),
USA300-0114, and USA300 (carrying the SCCmec IVb) were used as controls for comparisons
of PFGE banding patterns. Multilocus sequence typing (MLST) [28] was performed using
representatives isolates of each PFGE type and the presence of six CA-MRSA virulence-
associated genes (lukS-PV, lukF-PV, arcA, sek, seq, and bsaA) previously reported in the
USA300 (ST8) strain was investigated in all CA-MRSA isolates using PCR assays, and primers
described previously [29,30]. The USA300-0114 strain was used as a positive control for the
PCR amplifications.
RESULTS
Phenotypic characteristics of MRSA in Latin-American Hospitals
A total of 1890 consecutive S. aureus isolates was collected from 32 hospitals in four countries.
Overall, 320 isolates were not included in the study due to protocol violations which most
frequently were due to contamination, isolates from the same patient, source not included in
the protocol or misidentification. From the included isolates (total of 1570), Colombian
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hospitals contributed 707 (45%), Ecuador, 309 (20%), Peru, 287 (18%), and Venezuela, 267
(17%) of the isolates. Blood, secretions from surgical wound, and complicated SSTIs were the
most common sources of S. aureus isolates accounting for 27%, 26%, and 8%, respectively.
Methicillin resistance in S. aureus was found in 41% of isolates with geographic variations
(Peru, 62%; Colombia, 45%; Ecuador, 28%; Venezuela, 26%). Table 1 shows the percentage
of resistance to each class of antibiotic in the region and per country in S. aureus and in the
subset of MRSA isolates. Overall, MRSA isolates demonstrated high rates of resistance to
erythromycin (75%), clindamycin (72%), ciprofloxacin (72%), and gentamicin (69%). The
lowest rates of resistance were found to SXT (5%), rifampin (5%), and minocycline (1%). All
isolates were susceptible to linezolid and vancomycin (MIC90 1 μg/mL MIC, range 0.5–2 μg/
mL) by agar dilution method. Among 651 MRSA isolates evaluated, only 9 isolates (6 from
Peru, 2 from Colombia, and 1 from Ecuador) were found to be GISAs after the screening and
confirmatory methods were used.
Hospital vs. Community - Associated MRSA in the Andean Region
In order to differentiate the South American MRSA isolates with typical HA pulsotype (HA-
like) from those with a CA type (CA-like), the PFGE banding pattern of all isolates was
compared to that of representatives isolates of the most common HA clones previously
described in South-America (e.g., Chilean, Brazilian, Pediatric, and New York/Japan). Isolates
which were not genetically related to any of those clones (> 6 bands difference) were tested
for the presence of lukF-lukS genes (encoding PVL) and SCCmec IV, and organisms which
yielded a positive result for both were designated as CA-like strains and their PFGE pattern
compared to that of representatives of the USA300-0114 strain (SCCmec IVa), a USA300
strain carrying the SCCmec cassette IVb and a representative of USA400 (NRS 123). Using
these genotypic criteria, three groups of isolates were clearly identified: i) 461 isolates (71%)
were categorized as having a HA-like MRSA type; ii) 174 (27%) isolates were likely to be
CA-MRSA (CA-like MRSA) and, iii) 16 isolates (2%) showed patterns not related to the
circulating HA or CA clones previously characterized in the region and lacked the genes
encoding PVL. All MRSA isolates recovered in Peru had genotypic characteristics (see below)
of HA-like MRSA and we were unable to identify any isolate with a CA-like profile.
Conversely, 74% of MRSA isolates submitted from Ecuadorian centers had a CA-like
genotype. In Venezuela and Colombia, 14% and 31% of MRSA isolates recovered in hospitals
had characteristics compatible with CA-like MRSA, respectively (Table 2).
The HA-like MRSA group were mostly recovered from blood (30%) and PFGE analysis
revealed that the majority (92%) were clonally related to a major PFGE pulsotype, designated
pulsotype A in this work, which is related to the pattern previously observed for the Chilean
clone, which harbors the SCCmec type I and belongs to the sequence type 5 (ST5) by MLST.
SCCmec typing of 23 representative isolates from this clone recovered in different countries
confirmed the presence of SCCmec I and MLST of a representative isolate yielded the ST5,
confirming the genetic relatedness with the Chilean clone. Additionally, minor pulsotypes were
identified: i) pulsotype B, which corresponds to the Brazilian clone, was detected in 20 isolates
(4%), was the predominant HA-like clone found in Ecuadorian hospitals (62%) and was
identified in 4% of the HA-like MRSA isolates from Peru. Among isolates belonging to the
Brazilian clone (n=20), 90% harbored the SCCmec type III and were resistant to SXT, while
10% harbored the SCCmec I and were susceptible to SXT; ii) pulsotype C, corresponding to
the New York/Japan clone, was detected in 18 isolates (4%). Most (72%) of the pulsotype C
isolates were associated with SCCmec type II and the remaining isolates carried the SCCmec
type IV.
Amongst the CA-like MRSA group (174 isolates), secretions from SSTIs, surgical wound
infections and blood were the most common sources accounting for 26%, 25% and 18%,
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respectively, and we were able to identify four pulsotypes amongst these 174 CA-MRSA
isolates. The major pulsotype (designated ComA, figure 1) was detected in 167 (96%) isolates
(Table 3) and was the most common type in the four countries of the region, being found in
100%, 98%, and 50% of the CA-like MRSA from Ecuador, Colombia, and Venezuela,
respectively. The majority (81%) of CA-like MRSA isolates corresponding to the ComA
pulsotype were clonally related (≥6 bands difference) to the USA300 MRSA-ST8-IV epidemic
strain and representatives isolates were shown to belong to ST8. However, unlike the
USA300-0114 strain, the vast majority of these isolates (158 out of 167) carried a SCCmec
subtype other than IVa; when a different set of primers for SCCmec typing [24]was used (which
includes specific primers for the J1 region), a band corresponding to subtypes IVc/IVE was
found in the majority of these isolates (93%), suggesting that a different SCCmec IV variant
was present in CA-MRSA from South-America. The subtype IVa, typical of USA300-0114,
was only detected in 9 isolates (5%), and we were unable to determine a subtype (1%) in two
isolates. MLST of representative isolates from the pulsotype ComA confirmed that they
belonged to ST8 (Table 3) and we detected bsaA, sek, and seq in 99%, 95%, and 91% of these
isolates, respectively. Conversely, the majority of CA-like MRSA from the ComA clone lacked
the arcA gene (only present in 4% of the isolates), which is an indicator of the presence of the
arginine catabolic mobile element (ACME) typical of the USA300-0114 strain. An important
characteristic of these CA-like MRSA isolates was the high rates of resistance to tetracycline
(41%) found, but not minocycline (typical of the tet(K) determinant). Rates of resistance to
erythromycin (10%), clindamycin (4%), ciprofloxacin (5%), gentamicin (2%), SXT (4%),
chloramphenicol (1%), and rifampin (1%) were low. Of note, the highest rates of resistance to
antibiotics were found in CA-like MRSA isolates from Ecuador (Table 3). Four minor
pulsotypes which differed in ≥7 bands from the patterns of isolates USA300 MRSA-ST8-IV
were found amongst the rest of the isolates exhibiting CA-like characteristics; these were
designated ComB (ST6), ComC (SLV of ST5), ComD (ST22), and ComE (ST923, which had
only been described previously in Colombia) [15].
Among the remaining 16 isolates, whose PFGE pattern was unrelated to that of the HA or CA
patterns and which lacked the gene encoding PVL, we identified 12 pulsotypes (designated
DifA to DifL). Amongst these isolates, high rates of resistance to quinolones (69%),
erythromycin (62%), clindamycin (50%), and gentamicin (62%) were observed and
SCCmec types III and IV were found in most.
DISCUSSION
This multicentric study evaluated prospectively and systematically the phenotypic
characteristics and population genetics of MRSA in four Latin American countries of the
Andean region. The protocol was designed to include patient isolates consecutively submitted
to the clinical laboratory in each hospital under specific guidelines and clinical criteria for
collection to avoid the recovery of isolates that were likely to represent colonization. The
overall rate of isolation of MRSA was 41%, with important differences between countries. In
Colombia, the rate of MRSA in the participating 22 hospitals (from 6 cities across the country)
was 45%; this value is similar to a previous multicentric surveillance study (rates of 51%)
[31], indicating that the prevalence of MRSA in Colombia remains high. In contrast, the
participating centers and cities involved in the other countries were fewer, making
generalizations regarding rates of MRSA in those countries more difficult and raising the
possibility that the molecular epidemiology of the organisms recovered may be skewed by the
predominance of a particular strain in a given hospital. In Ecuador, for example (unlike the
other countries of the region), the local hospital clinical laboratories also receive and process
clinical samples from ambulatory services and outpatient clinics which likely influenced the
type of isolates that were collected. In fact, the majorities of clinical samples from Ecuador
originated from SSTIs and were likely from patients who were not in the hospital. Therefore,
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the rates of MRSA and the proportions of HA-like vs. CA-like MRSA circulating in the
Ecuadorian hospitals are difficult to estimate. Nonetheless, our aim was to determine the
population genetics of consecutive isolates submitted to a hospital clinical laboratory and the
findings indicate a high circulation of CA-like MRSA in Ecuador. Moreover, the limitations
specified above are common in this type of study which included centers from different
countries with heterogeneous populations and varied antibiotic prescribing policies.
The most striking finding of our study was that the highly virulent USA300 MRSA-ST8-IV
lineage (which includes the MRSA-ST923-IV, a SLV of ST8) was the predominant and almost
exclusive CA-like clone in this region of Latin America accounting for ca. 21% of MRSA
isolates. We had previously reported the emergence and dissemination of this USA300 clone
variant in Colombia, causing severe skin and soft tissue infections in outpatients with important
morbidity and mortality [15]. In this study, we confirmed that the same strain (exhibiting the
PFGE banding pattern ComA) has now been established in other Colombian hospitals
(accounting for 31% of their MRSA isolates) and also has now been identified in Ecuador and
Venezuela (100% and 50% of CA-like MRSA isolates, respectively). The South American
USA300 MRSA-ST8-IV has unique characteristics when compared to the USA300-0114
strain: i) it has a different SCCmec subtype cassette; ii) it appears to lack the ACME island and
iii) 41% of isolates exhibited resistance to tetracycline (although minocycline remained active)
while the rates of resistance to erythromycin were low. Our findings confirm that a USA300-
ST8 derivative genetic lineage has now been established in Latin America and support the
hypothesis that a highly virulent ancestral USA300-ST8 methicillin-susceptible S. aureus
strain, related to the USA300-0114, was likely present in this region of the continent and
subsequently acquired the SCCmec independently. Recently, it has been shown that the
USA300 lineage is a derivative of a progenitor strain USA500 [32] and it is tempting to
speculate that the South American USA300 variant may also be sublineage derivative of
USA500. Our results also indicate that the CA-MRSA lineage prevalent in this area of the
continent differs substantially from that of isolates found in the southern cone of South America
where MRSA-ST30-IV, and MRSA-ST5-IV derivatives appear to predominate [13,14,33]. A
single MRSA-ST22-IV isolate found in Venezuela (with the ComD pattern, Table 3) belongs
to one of the pandemic MRSA clones, referred as EMRSA-15 [7], predominant in United
Kingdom hospitals and characterized by a low frequency of multidrug resistance and the
presence of SCCmec IV; this clone has also been recently identified in isolates from non-
hospitalized patients in Europe [34]. Our results also indicate an important variation in the
molecular epidemiology of HA-MRSA in the Andean region. The HA Chilean clone (MRSA-
ST5-I) has now been successfully established in Colombia, Peru, and Venezuela. This clone
was first identified in Chile in the late 1990s [9], replaced the previously predominant
“Pediatric” clone in Colombian hospitals in a span of two years [12] and now is spreading to
the rest of the continent [8–11]. Of note, the New York/Japan (MRSA-ST5-II) clone was
detected in a few MRSA isolates (3%) from the region, and it is the first time that the presence
of this clone is reported in Latin America.
The vancomycin MIC90 of the MRSA isolates from this study was 1 μg/mL, which is identical
to that previously reported in Colombia [31], indicating that an obvious “MIC creep” [35] has
not occurred in MRSA from this region of Latin-America. We also report, for the first time,
the emergence of GISA isolates in the northern area of Latin-America (isolates with reduced
susceptibility to vancomycin had been previously reported in Brazil) after following a very
strict methodology that included three different methods of screening. Of interest, one of the
nine VISA isolates exhibited a CA genotype, supporting the finding that this phenotype may
also be present in MRSA USA300, as described previously [36].
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In conclusion, we present evidence that MRSA USA300 genetic lineage has now been
established as the almost exclusive CA-like clone in the northern region of South America,
and has now entered nosocomial settings in some countries.
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Figure 1.
Pulsed field gel electrophoresis (PFGE) of CA-like MRSA isolate representatives of the ComA
pulsotype from different countries. Lane 1, S. aureus NCTC 8325; lane 2, Col-177 (Colombia);
lane 3, HUV-01 (Colombia); lane 4, CA-12 (Colombia); lane 5, C609 (Colombia), lane 6,
V2125 (Venezuela); lane 7, E403 (Ecuador); lane 8, USA300-0114 strain; lane 9, USA300
varrying SCCmec IVb (Nebraska); lane 10, USA400 (N. Dakota); lane 11, S. aureus NCTC
8325.
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